Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Homidium is a phenanthridine derivative and small molecule trypanocidal agent primarily used in veterinary medicine since the 1950s to treat trypanosomiasis in cattle[1][7]. It acts as a DNA intercalating agent, disrupting the kinetoplast network of trypanosomes and thereby inhibiting cell division and leading to parasite death[1][6][8]. Homidium is most commonly administered as its bromide or chloride salts (homidium bromide/ethidium bromide or homidium chloride), which are also widely used as fluorescent nucleic acid stains in molecular biology[3][4][7]. Its use has declined due to increasing resistance among parasites. The drug is mainly therapeutic rather than prophylactic for animal trypanosomiasis[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on homidium.